(News Bulletin 247) – Barclays on Monday raised its advice on Sanofi, which it is changing from ‘online weighting’ to ‘overweighting’ following the ‘impressive’ clinical results unveiled last week concerning Dupixent in the treatment of COPD.
In a study devoted to the European pharmaceutical sector, the analyst now explains that he expects annual sales of 22 billion euros for Dupixent by 2030, against a forecast of 16.5 billion euros until then.
According to him, this development highlights the ‘value’ side of the Sanofi share, that is to say its weakly valued aspect compared to other titles such as GSK or Novartis.
“With investors increasingly concerned about the impact of the Inflation Reduction Act (IRA) on the sector, we consider Sanofi to be protected in the short term,” adds the intermediary. .
The legislation put in place in the United States within the framework of the IRA legislation provides for a cap on drug prices.
Morgan Stanley indicates that it has also raised its target price on the title, which goes from 90 to 115 euros.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
